Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis.
暂无分享,去创建一个
D. Mohr | R. Rudick | D. Goodkin | R A Rudick | D E Goodkin | D C Mohr | W. Likosky | W Likosky | N Gatto | K A Baumann | D. Mohr | K. Baumann | N. Gatto | Kristen A. Baumann
[1] J. Frank,et al. The effect of interferon‐β on blood—brain barrier disruptions demonstrated by constrast‐enhanced magnetic resonance imaging in relapsing—remitting multiple sclerosis , 1995, Annals of neurology.
[2] D. Goodkin. Interferon beta treatment for multiple sclerosis: persisting questions , 1996, Multiple sclerosis.
[3] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[4] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[5] C. Sherbourne,et al. Subthreshold depression and depressive disorder: clinical characteristics of general medical and mental health specialty outpatients. , 1994, The American journal of psychiatry.
[6] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[7] S. Poser,et al. Multiple sclerosis and gestation , 1983, Neurology.
[8] D. Mohr,et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment , 1996, Multiple sclerosis.
[9] D. Goodin,et al. Side effect profile of interferon beta-lb in MS , 1996, Neurology.